COHERUS ONCOLOGY INC (CHRS) Forecast, Price Target & Analyst Ratings
NASDAQ:CHRS • US19249H1032
1.78 USD
-0.17 (-8.72%)
At close: Mar 11, 2026
1.78 USD
0 (0%)
Pre-Market: 3/12/2026, 5:33:35 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COHERUS ONCOLOGY INC (CHRS).
Forecast Snapshot
Consensus Price Target
$5.78
+ 224.72% Upside
Next Earnings Forecast
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$0.21
Revenue Estimate16.3M
ChartMill Buy Consensus
83.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.78
Upside
+ 224.72%
From current price of $1.78 to mean target of $5.78, Based on 12 analyst forecasts
Low
$4.04
Median
$6.12
High
$7.35
Price Target Revisions
1 Month
0.00%
3 Months
13.33%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for CHRS. The average price target is 5.78 USD. This implies a price increase of 224.72% is expected in the next year compared to the current price of 1.78.
The average price target has been revised upward by 13.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.33%
CHRS was analyzed by 12 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CHRS.
In the previous month the buy percentage consensus was at a similar level.
CHRS was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-22 | Oppenheimer | Initiate | Outperform |
| 2025-09-04 | Maxim Group | Upgrade | Hold -> Buy |
| 2025-04-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-24 | UBS | Maintains | Neutral -> Neutral |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | Baird | Maintains | Outperform -> Outperform |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Baird | Maintains | Outperform -> Outperform |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | UBS | Downgrade | Buy -> Neutral |
| 2024-08-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-01 | Baird | Maintains | Outperform -> Outperform |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-23 | Truist Securities | Maintains | Buy -> Buy |
| 2024-01-23 | Baird | Maintains | Outperform -> Outperform |
| 2023-12-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-28 | Truist Securities | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$0.21
Revenue Estimate16.3M
Revenue Q2Q114.50%
EPS Q2Q38.80%
Number of Analysts7
Next Earnings Revisions
Revenue (1 Month)
0.04%
Revenue (3 Months)
-1.75%
EPS (1 Month)
0.00%
EPS (3 Months)
-0.72%
Next Earnings Summary
CHRS is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.21 USD and the consensus revenue estimate is 16.30M USD.
The next earnings revenue estimate has been revised downward by 1.75% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 211M -35.39% | 257.244M 21.92% | 266.96M 3.78% | 44.293M -83.41% | 79.565M 79.63% | 102.35M 28.64% | 189.56M 85.21% | 305.74M 61.29% | 424.18M 38.74% | 556.03M 31.08% | 697.82M 25.50% | 854.12M 22.40% | |
| EBITDA YoY % growth | -253.2M 2.76% | -194.508M 23.18% | -92.891M 52.24% | -180.54M -94.36% | -119.779M 33.66% | -55.549M 53.62% | -78.54M -41.39% | -55.08M 29.87% | -25.5M 53.70% | -14.28M 44.00% | -4.08M 71.43% | N/A | |
| EBIT YoY % growth | -256.9M 2.65% | -198.299M 22.81% | -98.167M 50.50% | -175.826M -79.11% | -137.414M 21.85% | -129.988M 5.40% | -125.859M 3.18% | -52.837M 58.02% | 50.454M 195.49% | 130.37M 158.39% | 235.54M 80.67% | 355.15M 50.78% | |
| Operating Margin | -121.75% | -77.09% | -36.77% | -396.96% | -172.71% | -127.00% | -66.40% | -17.28% | 11.89% | 23.45% | 33.75% | 41.58% | |
| EPS YoY % growth | -3.03 -163.48% | -2.02 33.33% | -0.75 62.87% | -1.47 -81.33% | -0.98 28.30% | -0.84 14.23% | -1.14 -36.59% | -0.93 18.75% | 0.13 114.29% | 0.57 330.77% | 1.16 103.57% | 1.79 53.51% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 38.80% | -0.15 55.00% | -0.25 23.76% | -0.17 51.00% |
| Revenue Q2Q % growth | 16.3M 114.50% | 31.181M 204.09% | 22.1M 90.99% | 22.703M 78.09% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -31.869M 29.86% | -29.388M 35.39% | -29.275M 33.97% | -29.4M 17.14% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
5.07%
EPS Next 5 Year
15.97%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
62.36%
Revenue Next 5 Year
57.12%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
12.47%
EBIT Next 5 Year
7.38%
COHERUS ONCOLOGY INC / CHRS Forecast FAQ
What is the average price target for COHERUS ONCOLOGY INC (CHRS) stock?
12 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 224.72% is expected in the next year compared to the current price of 1.78.
When does COHERUS ONCOLOGY INC (CHRS) report earnings?
COHERUS ONCOLOGY INC (CHRS) will report earnings on 2026-05-11.
Can you provide the consensus estimates for COHERUS ONCOLOGY INC next earnings?
The consensus EPS estimate for the next earnings of COHERUS ONCOLOGY INC (CHRS) is -0.21 USD and the consensus revenue estimate is 16.30M USD.
What is the expected long term growth rate for CHRS stock?
The expected long term growth rate for COHERUS ONCOLOGY INC (CHRS) is 62.36%.